Browsing Tag
Targeted Therapy
5 posts
Dizal’s sunvozertinib beats chemo in phase 3 first-line NSCLC trial, opening path to new drug applications
Dizal's sunvozertinib beats platinum chemo in WU-KONG28 phase 3 first-line EGFR exon 20 NSCLC trial. What this means for patients, rivals and investors. Read more.
Roche’s breast cancer pill inavolisib approved by MHRA for metastatic disease
MHRA approves inavolisib for advanced HR-positive breast cancer. Find out how Roche’s targeted therapy expands treatment options for UK patients.
Nuvalent (NASDAQ: NUVL) to release topline ALKOVE-1 trial data for neladalkib in advanced ALK-positive NSCLC on November 17
Nuvalent will present pivotal data for neladalkib in ALK-positive NSCLC on Nov 17. See what investors and analysts are expecting from ALKOVE-1.
BeiGene’s BRUKINSA gains accelerated FDA approval for follicular lymphoma treatment
In a significant development for patients with relapsed or refractory follicular lymphoma, BeiGene, Ltd. has announced the U.S.…
Amgen secures breakthrough therapy designation for sotorasib in China
Amgen has achieved a major milestone in the global development of its investigational KRAS G12C inhibitor, sotorasib, with…